Testosterone as Potential Effective Therapy in Treatment of Obesity in Men with Testosterone Deficiency: A Review

Farid Saad1,*, Antonio Aversa2, Andrea M. Isidori 2 and Louis J. Gooren3

1Bayer Pharma, Scientific Affairs Men’s Healthcare, Berlin, Germany and Gulf Medical University School of Medicine, Ajman, UAE
2Medical Pathophysiology and Endocrinology Section, Department of Experimental Medicine, Sapienza Università di Roma, Rome, Italy
3Department of Endocrinology, VUmc, Amsterdam, the Netherlands

Abstract:
Objective: Obesity negatively affects human health. Limiting food intake, while producing some weight loss, results in reduction of lean body mass. Combined with moderate exercise it produces significant weight loss, maintains lean body mass and improves insulin sensitivity, but appears difficult to adhere to. Bariatric surgery is clinically effective for severely obese individuals compared with non-surgical interventions, but has limitations. Clinical and pre-clinical studies have implicated a role for testosterone (T) in the patho-physiology of obesity.

Methods: Evidence Acquisition and Synthesis: A literature search in PubMed on the role of T in counteracting obesity and its complications.

Results: Obesity per se impairs testicular T biosynthesis. Furthermore, lower-than-normal T levels increase accumulation of fat depots, particularly abdominal (visceral) fat. This fat distribution is associated with development of metabolic syndrome (MetS) and its sequels, namely type 2 diabetes mellitus (T2DM) and cardiovascular disease (CVD). T treatment reverses fat accumulation with significant improvement in lean body mass, insulin sensitivity and biochemical profiles of cardiovascular risk. The contribution of T to combating obesity in hypogonadal men remains largely unknown to medical professionals managing patients with obesity and metabolic syndrome. Many physicians associate T treatment in men with risks for prostate malignancy and CVD. These beliefs are not supported by recent insights.

Conclusion: While overall treatment of obesity is unsuccessful, T treatment of hypogonadal men may be effective, also because it improves mood, energy, reduces fatigue and may motivate men to adhere to diet and exercise regimens designed to combat obesity.

Keywords: Obesity, metabolic syndrome, testosterone, diabetes mellitus, weight reduction, drug safety.

INTRODUCTION

Obesity is reaching epidemic proportions worldwide with profound impact on health resulting in reduced quality of life, early death. If obesity will continue to rise, it will undoubtedly increase healthcare costs and impede economic progress and national well being of many countries [1, 2]. Deposition of excess fatty acids (FAs) into fat cells in the form of triglycerides (TGs) is the biochemical basis of obesity, thus any imbalance in food intake and energy utilization may result in obesity. This homeostasis is complex and is regulated by a host of metabolic and endocrine factors which are poorly understood. Obesity contributes to pathologies, such as the metabolic syndrome (MetS), cardiovascular disease (CVD), type 2 diabetes mellitus (T2DM), hypertension, endothelial dysfunction [ED] and testosterone deficiency (hypogonadism) [TD]. Obese individuals often exhibit characteristics of MetS [3] with increased body mass index (BMI), waist circumference (WC) and waist-to-hip ratio (WHR).

Differences in gender distribution of body fat are well recognized [4] and in men, fat accumulates in the abdominal regions (both subcutaneous and intra-abdominal or visceral fat depots) and generally exhibits larger visceral fat depot relative to (premenopausal) women [5, 6]. In premenopausal women, a larger proportion of fat is stored in peripheral fat depots such as breasts, hips and thighs. Not surprisingly, sex steroids have been shown to contribute to this sex difference. Fat distribution (a large visceral fat depot) is a strong predictor of CVD and of the development of T2DM, and is also linked to a negative biochemical cardiovascular risk profile [7].

ROLE OF TESTOSTERONE IN ETIOLOGY, PATHO-PHYSIOLOGY AND TREATMENT OF MALE OBE-SITY

In addition to its role as a critical steroid hormone in reproductive and sexual functioning, T is an important signal-
ing molecule in regulating energy utilization and multiple cellular metabolic pathways, including nitrogen retention and regulation of adipogenesis [3, 8, 9]. Considerable evidence exists with regard to the role of T in increasing and maintaining muscle mass and reducing fat mass and therefore regulation of body composition [10]. This suggests that TD may contribute to the etiology of obesity and, in case of hypogonadism, T treatment may turn out to be beneficial in managing obesity, also in combination with exercise and diet [11, 12]. As shown in Fig. (1), testosterone treatment improves body composition. The potential of testosterone to improve the metabolic situation in hypogonadal has met with reservation. For many decades, T was perceived by the medical community to play a role in the development of prostate cancer (PCa) [13], and was thought of as a risk factor for CVD [14]. The higher prevalence of coronary heart disease in men, compared with women, was attributed to T, being the most obvious gender difference. Recent clinical studies have proven both assumptions inaccurate. There is no compelling evidence that T is a significant factor in the etiology of CVD [14] and of PCa [13], but once these unwarranted perceptions had become common they are difficult to discredit. In this review, we summarize the role of T in the etiology and treatment of obesity in men with TD from three perspectives: 1) evidence from epidemiological and observational studies, 2) evidence from androgen deprivation therapy (ADT), mainly in men undergoing treatment for PCa, and 3) evidence from T treatment of men with TD. Rather than to advocate testosterone in the large field of anti-obesity treatment, the aim is to define more precisely a role for testosterone in the treatment of obesity and its associated conditions in men with TD which has so far not received serious consideration. Naturally, the potential benefits must be balanced against its (long-term) risks.

**RELATIONSHIP BETWEEN TESTOSTERONE AND OBESITY**

TD (hypogonadism) in men is defined as a serum T less than 12 nmol/L [15] combined with a set of clinical signs and symptoms, as outlined by several professional societies [16]. Several studies have demonstrated an inverse relationship between indicators of obesity (body mass index, waist circumference, a reliable indicator of visceral obesity), and T levels over all age groups [3, 17, 18]. Obesity contributes to onset of T2DM, dyslipidemia, hypertension and, therefore, MetS. An inverse association between the severity of features of MetS, T2DM and plasma T has been previously reported [19]. In one study, this association was independent of age and body mass index [20], underlining the complexity of the relationship between testosterone and obesity [21]. This became also apparent from another study that verified the prevalence of low testosterone levels in male T2DM patients, related to variations in BMI, waist circumference, neuropathy, triglycerides, CRP, glucose and HOMA-IR, but no increase of silent myocardial ischemia or peripheral arterial disease was established [22]. This is supported by other studies linking low testosterone, cardiovascular risk and insulin resistance (for review [23]).

Although age is associated with the prevalence of MetS, young men with features of the MetS exhibit reduced T levels [24, 25] and T treatment in these individuals positively affects weight reduction, with concomitant reduction in insulin resistance (IR). The exact pathophysiological mechanisms responsible for reduced T levels in obesity remain under investigation [3], however, hyperinsulinemia is shown to suppress serum T levels [26]. T levels are reduced in men with T2DM [17], with an inverse association between T levels and glycosylated hemoglobin (HbA1c) [27] and this oc-
In men with low plasma T, the likelihood of T2DM is increased and several large prospective studies have shown that low T levels predict development of T2DM in men. Low levels of T are associated with a decreased lean body mass, and relative muscle mass is inversely associated with insulin resistance and prediabetes [29]. Epidemiological evidence from several longitudinal population studies shows that low T is an independent risk factor for the development of both MetS and T2DM [17, 28, 30], stroke or transient ischemic attacks [31]. A systematic review and meta-analysis of cross-sectional studies indicated that T level was significantly lower in men with T2DM (mean difference, -76.6 ng/dL, 95% confidence interval [CI], -99.4 to -53.6). Prospective studies have shown that men with higher T levels (range, 449.6-605.2 ng/dL) had a 42% lower risk of T2DM (RR, 0.58, 95% CI, 0.39 to 0.87). Reduced levels of total T and sex hormone binding globulin (SHBG) (associated with IR) were both independent risk factors in middle-aged men who later developed T2DM, according to The Massachusetts Male Aging Study (MMAS) and the Multiple Risk Factor Intervention Trial (MRFIT) [32, 33].

In The Rancho-Bernardo Study, a significant inverse correlation was demonstrated between baseline total T, with long-term (8-year follow-up) fasting glucose and insulin levels as well as glucose intolerance [34]. In men, endogenous testosterone concentrations were inversely related to mortality due to cardiovascular disease and all causes [35]. The authors concluded that low testosterone may be a predictive marker for those at high risk of cardiovascular disease. The Tromso study nuanced these observations [36]. In this study, there was a significant increase in all-cause mortality risk for men with free testosterone in the lowest quartile (<158 pmol/L) compared with the higher quartiles after age adjustment hazard ratios (HR 1.24, 95% confidence interval, CI 1.01-1.53) and after multivariate adjustments (HR 1.24, 95% CI 1.01-1.54). Total testosterone was not associated with mortality risk. Likewise, there were no significant changes in risk for first-ever MI across different total or free testosterone levels. Men with free testosterone levels in the lowest quartile had a 24% increased risk of all-cause mortality.

Recently, the Third National Health and Nutrition survey (NHANES III) in a population of 1,413 men after adjustment for age, race/ethnicity and adiposity, showed that those men initially in the lowest tertile of either free or bioavailable (but not total) T were approximately four times more likely to have T2DM compared to those in the third tertile [37]. Collectively, these findings support those reported by the MMAS in that the risk is independent of adiposity [17, 30, 31]. In a recent review and meta-analysis of endogenous testosterone and mortality in men, Araujo et al. concluded that low endogenous testosterone levels are associated with increased risk of all-cause and cardiovascular death in community-based studies of men, but with considerable between-study heterogeneity, which was related to study and subject characteristics, which suggests that effects are driven by differences between cohorts (e.g. in underlying health status) [38].

**THE VICIOUS CIRCLE OF LOW TESTOSTERONE AND OBESITY**

Synthesis of SHBG and T is a highly correlatively biochemical process. Hyperinsulinism, associated with adiposity, suppresses synthesis of SHBG and thus, levels of circulating T [39, 40]. In addition, insulin [41] and leptin [42] exert suppressive effects on testicular steroidogenesis and may contribute to further disruption of pulse amplitude of luteinizing hormone (LH) diminishing stimulation of the testicular steroidogenesis. Further, conversion of T to estradiol in adipose tissue resulting in elevated serum estradiol, may contribute to inhibition of androgen biosynthesis via central feedback mechanism involving the hypothalamus - pituitary gonadal axis [43]. It is well recognized that adipocytes secrete a host of adipokines that regulate a variety of metabolic processes in endocrine, paracrine and autocrine fashion. Thus, adipokytokines, secreted by visceral fat modulate the hypothalomo-pituitary-testicular axis and inhibit T production [44]. Modulation of GnRH secretion by Kisspeptins, produced by adipose tissue causes significant lowering circulating levels of T [45]. Clear and illustrative clinical examples for a role of T in the onset of MetS are demonstrated in patients with PCa undergoing ADT or in men with T2DM. This treatment is accompanied with decreased total lean body mass, increased total fat mass, and, particularly in the longer-term, the development of the MetS. More importantly, acute ADT reduces insulin sensitivity and strongly impairs glycemic control of men with T2DM [46, 47]. Thus, a vicious circle ensues in which MetS suppresses T biosynthesis and conversely, reduced T concentrations predispose and contribute to the onset of development of MetS [32] and in turn obesity.

**OBESITY, LOW TESTOSTERONE AND INFLAMMATION**

Visceral obesity is associated with insulin resistance (IR), hyperglycemia, atherogenic dyslipidemia, hypertension as well as pro-thrombotic and pro-inflammatory states. Adipose tissue is presently considered as an endocrine organ secreting various biochemical factors known as adipokines. The adipokines act via paracrine, autocrine and endocrine fashion influencing the metabolism of lipid, glucose homeostasis, and may influence cardiovascular risk factors, such as hypertension, as well as thrombotic and inflammatory processes. Tumor necrosis factor-alpha (TNF-α) and interleukin (IL)-6 are inflammatory markers secreted by adipocytes and contribute to the development of IR [48]. Reduced sex hormone levels are associated with increased inflammatory markers [49-51]. In elderly men, an inverse relationship between plasma T and inflammatory markers was observed [49]. Acute withdrawal of T in young, otherwise healthy hypogonadal patients, caused significant increases in IL-6 and TNF-α two weeks after cessation of T treatment. T treatment in men with lower-than-normal serum T reduces reduction in adipokines [50], though these are not observed in a short (three-month) study [51]. Whether the effect of T is via inhibition of differentiation of pluripotent cells into adipocytes or proliferation of pre-adipocytes, thus favoring myogenic differentiation [8] remains to be established. In short term studies, (< 3 months) T administration suppressed adiponectin levels [52] with a potentially adverse effect on
CVD risk. In patients with newly diagnosed T2DM, T treatment for one year was associated with an improvement of body composition and increased adiponectin levels [12] (Fig. 2).

**REDUCTION OF AGE-RELATED DECLINE IN TESTOSTERONE**

The age-related changes in neuroendocrine function diminish the efficacy of luteinizing hormone in stimulating Leydig cells [40]. An increasing body of evidence suggests that disease significantly contributes to the age-related decline of T [44, 53]. As shown in Fig. (2), changes in lifestyle (diet / exercise), leading to weight loss, might partially prevent or redress decline of androgen levels with aging [12]. Also Roux-en-Y gastric bypass surgery reduced body mass index and increased total and free T levels [54]. Apparently, body fat mass possesses the potential to lower serum T, reversible upon weight loss.

**TESTOSTERONE, ADIPOSE TISSUE AND LIPID METABOLISM**

Sex steroid hormones play an integral role in regulating cellular metabolism, accumulation and distribution of adipose tissues. Estrogens, progesterone and androgen receptors are expressed in adipose tissues. Sex steroid hormones regulate the function of adipose tissues by genomic and non-genomic signaling mechanisms. Activation of the cAMP cascade by sex steroid hormones would activate hormone-sensitive lipase leading to lipolysis in adipose tissues. Their activation appears to be involved in the control of pre-adipocyte proliferation and differentiation. T regulates lineage determination in mesenchymal pluripotent cells by promoting the myogenic lineage and inhibiting the adipogenic lineage [8]. T inhibits triglyceride uptake and lipoprotein lipase activity and causes a more rapid turnover of triglycerides in subcutaneous abdominal adipose tissue and less in femoral fat and, maybe, mobilizes lipids from the visceral fat depot [55].

**TREATMENT OF OBESE MEN WITH TESTOSTERONE: EFFECTS ON BODY COMPOSITION**

T is an important factor in the etiology of obesity, MetS and its associated diseases T2DM and atherosclerotic disease. The question arises whether T treatment in obesity and MetS and its sequels, such as T2DM and CVD is beneficial. There is increasing body of evidence indicating a beneficial effect of T treatment on visceral fat and other components of the MetS [56]. As shown in Tables 1 and 2, T administration improves many parameters associated with obesity and effects on lean body mass.

Changes in visceral fat appear to be related to changes in serum total T [57]. A number of randomized controlled trials have confirmed the beneficial effects of T on body composition and variables of the MetS. In a study of weekly administration of T enanthate 100 mg i.m., there was a significant increase in lean body mass, with a mean change in fat mass of 0.2 kg (n.s), and a decline of serum cholesterol. In an eight months study of 23 middle aged abdominally obese men, a decrease of visceral fat mass (without a change in body mass, subcutaneous fat mass or lean body mass) was observed. The net change of fat mass was -1.8 kg (-6.3%) (n.s.). IR improved and blood glucose, diastolic blood pressure and serum cholesterol decreased with T treatment [58]. In a study of 108 men over 65 years of age fat mass decreased (-2.9 kg, -11.9%; (p<0.001)) and lean mass increased subsequent to T treatment [59]. Similar results were obtained in other studies [60-68]. In a study of 70 men over 36 months, T treatment increased lean body mass, decreased fat mass (-4.5 kg; -16%), decreased total cholesterol, low-density lipoprotein, and leptin [69]. A reduction in leptin and

---

**Fig. (2).** Waist circumference in 32 men with newly diagnosed type 2 diabetes in the DIMALITE (Diabetes Management by Lifestyle and Testosterone) study. Adapted from reference [12].
Table 1. Changes in Parameters of Obesity Upon Testosterone (T) Treatment Versus Placebo (Plc).

| Reference / Parameter | Preparation | Treatment Duration | Change T | Change Plc | Net Change |
|-----------------------|-------------|--------------------|----------|------------|------------|
| **Total fat mass (kg)** |             |                    |          |            |            |
| Marin 1993 [58]       | Gel         | 9 mo               | -1.8     | 0.6        | -2.4       |
| Snyder 1999 [59]      | Patch       | 36 mo              | -3.3     | -1.3       | -2.0       |
| Kenny 2001 [62]       | Patch       | 12 mo              | -1.7     | 0.3        | -1.4       |
| Ferrando 2002 [63]    | TE          | 6 mo               | -3.6     | 0.3        | -3.9       |
| Boyanov 2003 [64]     | Oral TU     | 3 mo               | -1.65    | -0.25      | -1.4       |
| Crawford 2003 [65]    | Mixed esters| 12 mo              | -2.3     | 0.7        | -3.0       |
| Steidle 2003 [66]     | Gel         | 3 mo               | -0.8     | -0.1       | -0.7       |
| Steidle 2003 [66]     | Patch       | 3 mo               | -0.4     | -0.1       | -0.3       |
| Witteri 2003 [61]     | Oral TU     | 12 mo              | -0.2     | 0.85       | -1.05      |
| Casaburi 2004 [67]    | TE          | 10 wk              | -1.01    | -0.08      | -0.93      |
| Casaburi 2004 [67]    | TE          | 10 wk              | -1.41    | -0.13      | -1.28      |
| Svartberg 2008 [71]   | Inj TU      | 12 mo              | -5.4     | -0.6       | -4.8       |
| Allan 2008 [57]       | Patch       | 12 mo              | -0.5     | 0.1        | -0.6       |
| Emmelot-Vonk 2008 [10]| Oral TU     | 6 mo               | -1.0     | -0.1       | -0.9       |
| Srinivas-Shankar 2010 [68]| Gel&emsp;&emsp;| 6 mo               | -0.8     | -0.3       | -0.5       |
| **Visceral adipose tissue (kg)** |             |                    |          |            |            |
| Marin 1993 [58]       | Gel         | 9 mo               | -0.6     | 0.2        | -0.8       |
| Allan 2008 [57]       | Patch       | 12 mo              | -0.2     | 0.5        | -0.7       |
| **Trunk fat (kg)**    |             |                    |          |            |            |
| Casaburi 2004 [67]    | TE          | 10 wk              | -0.55    | 0.34       | -0.89      |
| Casaburi 2004 [67]    | TE          | 10 wk              | -0.67    | 0.11       | -0.78      |
| Page 2005 [69]        | TE          | 36 mo              | -1.9     | -0.4       | -1.5       |
| Allan 2008 [57]       | Patch       | 12 mo              | 0.1      | 0.0        | 0.1        |
| **Visceral adipose tissue (cm³)** |             |                    |          |            |            |
| Svartberg 2008 [71]   | Inj TU      | 12 mo              | -38      | -11        | -27        |
| **Subcutaneous adipose tissue (kg)** |             |                    |          |            |            |
| Marin 1993 [58]       | Gel         | 9 mo               | -1.2     | 0.5        | -1.7       |
| Allan 2008 [57]       | Patch       | 12 mo              | -0.1     | 0.0        | -0.1       |
| **Subcutaneous adipose tissue (cm³)** |             |                    |          |            |            |
| Svartberg 2008 [71]   | Inj TU      | 12 mo              | -49      | -10        | -39        |
| **Total adipose tissue (cm³)** |             |                    |          |            |            |
| Svartberg 2008 [71]   | Inj TU      | 12 mo              | -86      | -27        | -59        |
| **Right leg fat (kg)** |             |                    |          |            |            |
| Page 2005 [69]        | TE          | 36 mo              | -0.9     | 0.1        | -1.0       |
| **Percentage total body fat (%)** |             |                    |          |            |            |
| Sih 1997 [84]         | TC          | 12 mo              | -1.9     | 19.3       | -21.2      |
also of adiponectin was found upon T administration to men with TD with or without T2DM [51]. T therapy reduced waist circumference (-1.63 ± 0.71 cm, p = 0.03) and waist/hip ratio (-0.03 ± 0.01, p = 0.01), improved IR and glycemic control in men with TD and T2DM [51, 70]. T treatment reduced fat mass (-5.4±2.4 kg) and abdominal adipose tissue and increased fat-free mass in a one-year study [71] (Fig. 1). T treatment selectively lessened visceral fat accumulation without change in total body fat mass and increased total body fat free mass and total body and thigh skeletal muscle mass in a study of men over 55 years over 52 weeks [57]. Interestingly, a monthly cycled T regimen using half the T dose compared to the standard care of continuous therapy, improved body composition and increased muscle strength similarly to continuous T [72].

A study of T administration in 207 men over 6 months reported an increase in lean body mass and a decrease in fat mass (-1.3 kg; range -1.8 to 0.8) and a decrease in fat mass percentage (-1.7%, range -2.1—1.1) [10]. The above studies have been conducted in men with low serum T but there are two studies demonstrating a beneficial effect of T administration in men whose serum T is not subnormal but in the low range of normal [57, 58]. In a double blind, placebo-controlled study over a 6-month period, transdermal T treatment was associated with beneficial effects on insulin resistance, total and LDL-cholesterol, lipoprotein(a), and sexual health in hypogonadal men with type 2 diabetes and/or MetS [73].

Characteristics of the obese person co-determine the effects of T administration. BMI was significantly associated
Table 2. Changes in Lean Mass Upon Testosterone (T) Treatment Versus Placebo (Plc).

| Reference / Parameter | Preparation  | Treatment Duration | Change T | Change Plc | Net Change |
|-----------------------|--------------|--------------------|----------|------------|------------|
| Marin 1993 [58]       | Gel          | 9 mo               | 1.5      | 0.2        | 1.3        |
| Snyder 1999 [59]      | Patch        | 36 mo              | 2.1      | -0.3       | 2.4        |
| Kenny 2001 [62]       | Patch        | 12 mo              | 1.0      | 0.2        | 0.8        |
| Crawford 2003 [65]    | Mixed esters | 12 mo              | 1.8      | -0.5       | 2.3        |
| Ferrando 2003 [63]    | TE           | 6 mo               | 4.2      | -2         | 6.2        |
| Steidle 2003 [66]     | Gel          | 3 mo               | 1.7      | 0.6        | 1.1        |
| Steidle 2003 [66]     | Patch        | 3 mo               | 0.9      | 0.6        | 0.3        |
| Wittert 2003 [61]     | Oral TU      | 12 mo              | 1.0      | -1.0       | 2.0        |
| Casaburi 2004 [67]    | TE           | 10 wk              | 2.3      | -0.21      | 2.51       |
| Casaburi 2004 [67]    | TE           | 10 wk              | 3.29     | 0.2        | 3.09       |
| Page 2005 [69]        | TE           | 36 mo              | 3.7      | 0.0        | 3.7        |
| Kapoor 2006 [70]      | Mixed esters | 3 mo               | 1.23     | 0.67       | 0.56       |
| Svarberg 2008 [71]    | Inj TU       | 12 mo              | 4.2      | 0.4        | 3.8        |
| Allan 2008 [57]       | Patch        | 12 mo              | 0.8      | -0.3       | 1.1        |
| Emmelot-Vonk 2008 [10]| Oral TU      | 6 mo               | 1.1      | -0.3       | 1.4        |
| Srinivas-Shankar 2010 [68]| Gel | 6 mo | 1.1 | -0.2 | 1.3 |
| Aversa 2010 [85]      | Inj TU       | 24 mo              | 4.8      | -0.1       | 4.9        |
| Aversa 2010 [87]      | Inj TU       | 12 mo              | 4.2      | -0.6       | 4.8        |

Gel: testosterone gel  
Patch: testosterone patch  
TE: parenteral testosterone enanthate  
Oral TU: oral testosterone undecanoate  
Mixed esters: mixed parenteral testosterone esters  
Inj TU: parenteral testosterone undecanoate

with the benefit of T treatment on all variables measured except on C-reactive protein [74, 75]. Waist circumference also showed these associations, but BMI appeared to be a slightly stronger predictor than baseline waist circumference (Fig. 3), it is of utmost interest to indicate that in all three anthropometric parameters there is a progressive improvement in the group of men treated with T. In contrast, the placebo group shows initial improvement after 18 weeks which returns toward baseline levels only 12 weeks later, indicating the transient effect of the physician’s advice to improve lifestyle [74].

**TESTOSTERONE, DIET AND EXERCISE AND WEIGHT LOSS**

The successes of interventions to achieve long-term weight loss in obese men are conflicting and most often disappointing. In a systematic review and meta-analysis of subjects of 60 years or above a modest but significant weight loss of 3.0 kg [95% confidence interval (CI) 5.1-0.9] at 1 year was noted [76]. Another very thorough review reported weight loss in various populations of between 0.04 and 4.9 kg [77]. Total cholesterol did not show a significant change: -0.36 mmol/l (95% CI -0.75 to 0.04). There was no significant change in high-density lipoprotein, low-density lipoprotein or triglycerides. In one study, recurrence of hypertension or cardiovascular events was significantly reduced (hazard ratio 0.65, 95% CI 0.50-0.85). Six-minute walk test did not significantly change in one study. Health-related quality of life significantly improved in one study [70] but did not improve in a second study [73]. The expectations for weight loss in overweight patients are several hundred percent higher than achieved in real life. All these studies did not include baseline T levels as an inclusion/exclusion criterium neither variation from baseline as an endpoint.

Weight loss interventions without changes in aerobic capacity do not appear to enhance muscle oxidative capacity in obesity. There is an increased capacity of intracellular fatty acid transport in skeletal muscle cells in the physiological adaptations of fat metabolism to energy restriction in obesity. In obesity-related IR, the metabolic capacity of skeletal muscle appears to be organized towards fat esterification rather than oxidation and dietary-induced weight loss does
not correct this disposition [78]. Mitochondrial electron transport chain (ETC) activity in skeletal muscle in previously sedentary obese men and women was substantially improved by an intervention of moderate weight loss and moderate intensity of physical activity. These biochemical changes in skeletal muscle mitochondria occurred in conjunction with improvement in substrate metabolism and insulin sensitivity in muscle. Interestingly, the increase in ETC activity in skeletal muscle in these previously sedentary obese men and women was greater than that of mitochondrial DNA content, signifying a more pronounced effect on functional capacity of mitochondria than on proliferation [78, 79]. Diet-induced weight loss significantly decreases muscle mass in older adults. However, the addition of moderate aerobic exercise to intentional weight loss attenuates the loss of muscle mass [78]. In a systematic review assessing the effects of energy restriction and exercise on fat-free mass in overweight and obese middle-aged and older adults, it was concluded that exercise is an effective tool in men and women to preserve fat free mass and to combat sarcopenia [78]. In a systematic review assessing the effects of energy restriction and exercise on fat-free mass in overweight and obese middle-aged and older adults, it was concluded that exercise is an effective tool in men and women to preserve fat free mass and to combat sarcopenia [78].

Fig. (3). Absolute changes in anthropometric parameters in the double-blind, placebo-controlled Moscow study in 184 men with metabolic syndrome. Adapted from reference [74].

T may exert a dual effect on metabolism with an acute improvement in insulin sensitivity that occurs rapidly within a few days to few weeks of treatment, and before loss of fat mass becomes evident; and a prolonged effect achieved when a significant reduction of total and visceral body fat occurs [86, 87]. Given the fact that T replacement will promote a more active life-style, the rapid effects are needed to prepare the body to greater energy expenditure. In fact, physicians treating obesity should be aware of the risks of recommending physical exercise or intensive training to obese men with TD. In view of the importance of T in bone and muscles homeostasis, it is evident that obese men should receive androgen replacement prior to commencing physical training [88].
SAFETY OF TESTOSTERONE THERAPY

Studies to prove long-term safety of T have not been performed and will not be performed shortly because of logistics and budgetary problems. Physicians hesitate to prescribe T to men over the age of 50 years fearing it will induce PCa. Recent findings have placed such fear in a more rational perspective. T treatment in men [89] did not exacerbate voiding symptoms due to benign prostatic hyperplasia. The occurrence of PCa after T administration in (elderly) men has been reported, mostly in case reports [90]. By contrast, a host of studies, using various designs and T formulations, over periods ranging from several months to 15 years, in men with a wide range of ages, have not revealed an increased risk of PCa [91]. A meta-analysis found that T treatment in older men compared to placebo was not associated with a significantly higher risk of detection of PCa [89], although the frequency of prostate biopsies was much higher in the T-treated group than in the placebo group [89]. There is no convincing evidence that T is the main factor in the development or progression of PCa in men [92, 93]. But as indicated above, the definitive studies to define the safety of T have not been carried out. Guidelines for monitoring have been developed which, if rigorously applied, render T treatment to be a safe therapy in men without (a prior history of) PCa.

T produces a dose dependent effect on hemoglobin and hematocrit values [94], apparent in a number of studies, and remarkably, this effect is more pronounced in older men [95-97]. Though an elevated hematocrit is associated with stroke, and coronary heart disease, a relation between increased hematocrit as a result of androgen supplementation as such and an increased risk for stroke or any cardiovascular event in general has not been demonstrated by large meta-analyses of placebo-controlled trials of T administration to (elderly) men [14, 89]. Polycythemia is a manageable risk of androgen administration when hemoglobin levels and hematocrit are monitored and the dose of T is adjusted.

Until a decade ago, it was a widely held belief that androgens have an atherogenic effect and thus led to CVD, and androgen therapy was regarded a risk of developing CVD. Over the last decade several studies have examined the relationship of androgens with CVD and concluded that it is no longer tenable to regard T as a culprit in the etiology of CVD [98, 99]. The study of Basaria et al. [100] has drawn new attention to the potential cardiovascular risks of T administration to elderly frail men, but the study has also been critically examined for a number of potential biases, addressed in a recent review [101].

T therapy in elderly men may be viewed as a responsible practice provided certain guidelines produced by professional scientific and clinical organizations are followed with regard to T therapy in elderly men [16]. This consensus is based on expert opinion and, therefore, the need for longer-term safety studies remains urgent.

FUTURE PERSPECTIVE

Obesity is a growing health problem worldwide. It impairs health and thus quality of life. Treatment is far from simple. Obesity produces a host of metabolic changes at the molecular and cellular levels in a host of tissues, including the skeletal muscle. These metabolic changes bring about programmed cell death and increased inflammatory markers and produce a vicious cycle that contributes to TD and obesity (Fig. 4). The link between IR, obesity and MetS and the onset of T2DM is well established, however the exact cellular mechanisms remain under extensive investigations.

Diet treatment is only marginally successful and leads to loss of muscle mass, which may be prevented by combining diet with exercise. Although treatment of obesity by lifestyle interventions in high risk patients, especially those at high risk for T2DM is highly recommended, it is usually little successful and of limited clinical benefit. Pharmacological treatment is only modestly successful and not without car-

---

**Fig. (4).** The vicious cycle of testosterone deficiency and obesity. Adapted from Jones TH. Pract Diab Int 2007; 24(5): 269-277.
diovascular side effects [102]. A substantial number of obese men with T2DM exhibit reduced androgen levels. In these subjects, T treatment reduces fat mass and increases lean body mass and very likely also improves insulin sensitivity. T treatment improves muscle mass, reduces fat mass and muscle strength and physical performance. In addition, T increases motivation and decreases fatigue [103] and may therefore enable men to better adhere to an exercise programme. Thus, T may represent a useful tool in managing obesity in hypogonadal men when used together with diet and exercise.

There is as yet a lack of definition of a level of testosterone for initiating safe supplementation therapy in patients who are obese but do not suffer from testosterone deficiency symptoms. It is of note that in aging men, psychosomatic complaints and metabolic risk relate to levels of testosterone in a symptom-specific manner; some symptoms appear above the lower cut-off levels for the reference range of T [104]. But, until more specific information is available, T treatment should be limited to men with established biochemical criteria of TD [15, 16]. A recent study provided quantitative information. The mean (SD), median (quartile), and 2.5th percentile values were 723.8 (221.1), 698.7 (296.5), and 348.3 ng/dl for total T and 141.8 (45.0), 134.0 (60.0), and 70.0 pg/ml for FT, respectively, clinically validated by the fact that in all three samples, men with low TT and FT were more likely to have slow walking speed, difficulty climbing stairs, or frailty and diabetes [15]. But beneficial effects on features of the metabolic syndrome have been encountered in men with serum T levels above the lower limit of reference values [57, 105].

T treatment has positive effects on a number of parameters of cardiovascular health, such as serum LDL-cholesterol, blood pressure and heart rate [98]. Physicians managing overweight patients and its sequels (T2DM, CVD) are either unfamiliar or unaware of the physiology and pathophysiology of TD and its impact on body composition, the potential of T treatment in men with MetS and its sequels is not seriously considered as an option. Although comparison studies are lacking, the magnitude of changes obtained with T replacement therapy appear superior (or at least as effective as) most drugs used to reduce excess fat mass. A significant aspect of treating men with TD is the mood-elevating action of T in men with MetS who are often depressed and dysphoric. This aspect may bolster motivation to lose weight by adhering to a regimen of diet and exercise. Finally, recommending exercise to men with TD, for weight reduction, may expose these patients to severe risks [88]. To establish T therapy as a legitimate medical tool in the management of obesity in men with TD, more specific studies will be required by the regulatory agencies. These studies should convincingly demonstrate that abdominal obesity and MetS are ameliorated by normalizing T levels in hypogonadal men. Such studies should be up to the level of at least phase three to assess the efficacy with more narrow confidence intervals and to provide long-term safety data.

CONTRIBUTIONS OF THE AUTHORS

All authors have made equal contributions to the conceptualization of this review. Louis Gooren has taken main responsibility for writing the paper while the others have made critical reviews of the contents.

CONFLICTS OF INTEREST

Farid Saad is an employee of Bayer Pharma AG, manufacturer of the depot formulation of testosterone undecanoate. Louis Gooren has received honoraria for lectures and consultancy from Bayer Pharma. Antonio Aversa is a consultant for Pfizer, Lilly Inc. and Bayer Pharma. No funding was received for the preparation of this manuscript.

LIST OF ABBREVIATIONS

| Abbreviation | Definition |
|--------------|------------|
| ADT          | Androgen Deprivation Treatment |
| BMI          | Body mass Index |
| CI           | Confidence Interval |
| CVD          | Cardiovascular Disease |
| ED           | Endothelial Dysfunction |
| ETC          | Electron Transport Chain |
| FA           | Fatty Acids |
| HbA1c        | Glycated Hemoglobin |
| IL-6         | Interleukin 6 |
| IR           | Insulin Resistance |
| LH           | Luteinizing Hormone |
| MetS         | Metabolic Syndrome |
| MMAS         | Massachusetts Male Aging Study |
| MRFIT        | Multiple Risk Factor Intervention Trial |
| NHANES III   | Third National Health and Nutrition Survey |
| PCa          | Prostate Cancer |
| SHBG         | Sex Hormone Binding Globulin |
| T            | Testosterone |
| TD           | Testosterone Deficiency |
| TNF-α        | Tumor Necrosis Factor-alpha |
| T2DM         | Diabetes Mellitus Type 2 |
| WC           | Waist Circumference |
| WHR          | Waist/Hip Ratio |

REFERENCES

[1] Kypreos KE. Mechanisms of obesity and related pathologies. Feb J 2009; 276: 5719.
[2] Freedman DH. How to fix the obesity crisis. Sci Am 2011; 304: 40-7.
[3] Traish AM, Feeley RJ, and Guay A. Mechanisms of obesity and related pathologies: androgen deficiency and endothelial dysfunction may be the link between obesity and erectile dysfunction. Feb J 2009; 276: 5755-67.
[4] Blouin K, Boivin A, Tchernof A. Androgens and body fat distribution. J Steroid Biochem Mol Biol 2008; 108: 272-80.
[5] Stevens J, Katz EG, Huxley RR. Associations between gender, age and waist circumference. Eur J Clin Nutr 2010; 64: 6-15.
[6] Wells JC. Sexural dimorphism of body composition. Best Pract Res Clin Endocrinol Metab 2007; 21: 415-30.
Obesity and Testosterone

Current Diabetes Reviews, 2012, Vol. 8, No. 2  141

[7] Kramer CK, von Muhlen D, Gross JL, Barrett-Connor E. A prospective study of abdominal obesity and coronary artery calcium progression in older adults. J Clin Endocrinol Metab 2009; 94: 5039-44.

[8] Singh R, Artaza JN, Taylor WE, et al. Testosterone inhibits adipogenesis in 3T3-L1 cells: nuclear translocation of androgen receptor complex with beta-catenin and T-cell factor 4 may bypass canonical Wnt signaling to down-regulate adipogenic transcription factors. Endocrinology 2006; 147: 141-54.

[9] Traish AM, Tosenli P, Jeong SJ, Kim MN. Adipocyte accumulation in peri-capsular carnosum of the orchietomized rabbit: a potential mechanism for vaso-occlusive dysfunction in androgen deficiency. J Androl 2005; 26: 242-4.

[10] Ermolot-Vonk MH, Verhaar HJ, Nakhi Pour HR, et al. Effect of testosterone supplementation on functional mobility, cognition, and other parameters in older men: a randomized controlled trial. JAMA 2008; 299: 39-52.

[11] Bhasin S, Storer TW, Berman N, et al. The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. N Engl J Med 1996; 335: 1-7.

[12] Heufelder AE, Saad F, Bunck MC, Gooren L. Fifty-two-week treatment with diet and exercise plus transdermal testosterone reverses the metabolic syndrome and improves glycemic control in men with newly diagnosed type 2 diabetes and subnormal plasma testosterone. J Androl 2009; 30: 726-33.

[13] Morgentaler A, Traish AM. Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth. Eur Urol 2009; 55: 310-20.

[14] Fernandez-Balsells MM, Murad MH, Lane M, et al. Clinical review: adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab 2010; 95: 2560-75.

[15] Bhasin S, Pencina M, Jasuja GK, et al. Reference ranges for testosterone in men generated using liquid chromatography tandem mass spectrometry in a community-based sample of healthy nonobese young men in the Framingham Heart Study and applied to three geographically distinct cohorts. J Clin Endocrinol Metab 2011; 96: 2430-9.

[16] Wang C, Nieschlag E, Swerdloff R, et al. Investigation, Treatment, and Monitoring of Late-Onset Hypogonadism in Males: ISA, IS-SAM, EAU, EAA, and ASA Recommendations. Eur Urol 2009; 55: 121-130.

[17] Traish AM, Saad F, Guay A. The dark side of testosterone deficiency: II. Type 2 diabetes and insulin resistance. J Androl 2009; 30: 23-32.

[18] Corona G, Mannucci E, Ricca V, et al. The age-related decline of testosterone is associated with different specific symptoms and signs in patients with sexual dysfunction. Int J Androl 2009; 32: 720-8.

[19] Dhdinda S, Miller MG, McWhirter CL, et al. Testosterone concentrations in diabetic and nondiabetic obese men. Diabetes Care 2010; 33: 1186-92.

[20] Corona G, Monami M, Rastrelli G, et al. Testosterone and metabolic syndrome: a meta-analysis study. J Sex Med 2011; 8: 272-83.

[21] Cattabiani C, Basaria S, Ceda GP, et al. Relationship between Testosterone deficiency and Cardiovascular risk and Mortality in Adult Men. J Endocrinol Invest Nov 8, [Epub ahead of print] 2011.

[22] Hernandez-Mijares A, Garcia-Malpartida K, Sola-Izquierdo E, et al. Testosterone levels in males with type 2 diabetes and their relationship with cardiovascular risk factors and cardiovascular disease. J Sex Med 2010; 7: 1954-64.

[23] Aversa A. Drugs targeted to improve endothelial function: clinical correlates between sexual and internal medicine. Curr Pharm Des 2008; 14: 3698-9.

[24] Taneli E, Ersoy B, Ozhan B, et al. The effect of obesity on testicular function by insulin-like factor 3, inhibin B, and leptin concentrations in obese adolescents according to pubertal stages. Clin Biochem 2010; 43: 1236-40.

[25] Birkebaek NH, Lange A, Holland-Fischer P, et al. Effect of weight reduction on insulin sensitivity, sex hormone-binding globulin, sex hormones and gonadotrophins in obese children. Eur J Endocrinol 2010; 163: 895-900.

[26] Pasquali R, Macor C, Vicennati V, et al. Effects of acute hyperinsulinemia on testosterone serum concentrations in adult obese and normal-weight men. Metabolism 1997; 46: 526-9.

[27] Stamler J, Stamler R, Riedlinger WF, Algera G, Robert H. Hypertension screening of 1 million Americans. Community Hypertension Evaluation Clinic (CHEC) program, 1973 through 1975. Jama 1976; 235: 2299-306.

[28] Stanworth RD, Kapoor D, Chanmer KS, Jones TH. Statin therapy is associated with lower total but not bioavailable or free testosterone in men with type 2 diabetes. Diabetes Care 2009; 32: 541-6.

[29] Srikantapan, Karlamangla AS. Relative muscle mass is inversely associated with insulin resistance and prediabetes. Findings from the third national health and nutrition examination survey. J Clin Endocrinol Metab 2011; 96: 2989-903.

[30] Traish AM, Guay A, Feeley R, Saad F. The dark side of testosterone deficiency: I. Metabolic syndrome and erectile dysfunction. J Androl 2009; 30: 10-22.

[31] Yeap BB, Hyde Z, Almeida OP, et al. Lower testosterone levels predict incident stroke and transient ischemic attack in older men. J Clin Endocrinol Metab 2009; 94: 2353-9.

[32] Stellato RK, Feldman HA, Handy O, Horton ES, McKinlay JB. Testosterone, sex hormone-binding globulin, and the development of type 2 diabetes in middle-aged men: prospective results from the Massachusetts male aging study. Diabetes Care 2000; 23: 490-4.

[33] Haffner SM, Shaten J, Stern MP, Smith GD, Kuller L. Low levels of sex hormone-binding globulin and testosterone predict the development of non-insulin-dependent diabetes mellitus in men. MRFFIT Research Group. Multiple Risk Factor Intervention Trial. Am J Epidemiol 1996; 143: 889-97.

[34] Oh JY, Barrett-Connor E, Wedick NM, Wingard DL. Endogenous sex hormones and the development of type 2 diabetes in older men and women: the Rancho Bernardo study. Diabetes Care 2002; 25: 55-60.

[35] Khaw KT, Dassow M, Folkert E, et al. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) Prospective Population Study. Circulation 2007; 116: 2694-701.

[36] Viskan T, Schirmer H, Njolstad I, Svartberg J. Endogenous sex hormones and the protective association with cardiovascular disease and mortality in men: the Tromso Study. Eur J Endocrinol 2009; 161: 435-42.

[37] Selvin E, Feinleib M, Zhang L, et al. Androgens and diabetes in men: results from the Third National Health and Nutrition Examination Survey (NHANES III). Diabetes Care 2007; 30: 234-8.

[38] Araujo AB, Dixon JM, Suarez EA, Murad MH, Guey LT, Wittert GA. Clinical review: Endogenous testosterone and mortality in men: a systematic review and meta-analysis. J Clin Endocrinol Metab 2011; 96: 3007-19.

[39] Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005; 365: 1415-28.

[40] Kaufman JM and Vermeulen A. The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr Rev 2005; 26: 833-76.

[41] Pitteloud N, Hardin M, Dwyer AA, et al. Increasing insulin resistance is associated with a decrease in Leydig cell testosterone secretion in men. J Clin Endocrinol Metab 2005; 90: 2636-41.

[42] Isidori AM, Caprio M, Strollo F, et al. Leptin and androgens in male obesity: evidence for leptin contribution to reduced androgen levels. J Clin Endocrinol Metab 1999; 84: 3673-80.

[43] Mah PM and Wittt GA. Obesity and testicular function. Mol Cell Endocrinol 2010; 316: 180-6.

[44] Wu FC, Tajar A, Pye SR, et al. Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European Male Aging Study. J Clin Endocrinol Metab 2008; 93: 2737-45.

[45] George JT, Millar RP, Anderson RA. Hypothesis: kisspeptin mediates male hypogonadism in obesity and type 2 diabetes. Neuroendocrinology 2010; 91: 302-7.

[46] Hamilton EJ, Giannati E, Strauss BJ, et al. Increase in visceral and subcutaneous abdominal fat in men with prostate cancer treated with androgen deprivation therapy. Clin Endocrinol (Oxf) 2011; 74: 377-83.

[47] Levine GN, D’Amico AV, Berger P, et al. Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. Circulation 2010; 121: 833-40.
Lee DE, Kelenbrink S, Lee H, Hawkins M, Yudkin JS. Getting the message across: mechanisms of physiological cross talk by adipose tissue. Am J Physiol Endocrinol Metab 2009; 296: E1210-29.

Nettleship JE, Pugh PJ, Channer KS, Jones T, Jones RD. Inverse relationship between serum levels of interleukin-1beta and testosterone in men with stable coronary artery disease. Horm Metab Res 2007; 39: 366-71.

Corrales JJ, Almeida M, Burgo R, Mories MT, Miralles JM, Orfao A. Androgen-replacement therapy depresses the ex vivo production of inflammatory cytokines by circulating antigen-presenting cells in aging type-2 diabetic men with partial androgen deficiency. J Endocrinol 2006; 189: 595-604.

Kapoor D, Clarke S, Stanworth R, Channer KS, Jones TH. The effect of testosterone replacement therapy on adipokines and C-reactive protein in hypogonadal men with type 2 diabetes. Eur J Endocrinol 2007; 156: 595-602.

Page ST, Herbst KL, Amory JK, et al. Testosterone administration suppresses adiponectin levels in men. J Androl 2005; 26: 85-92.

Travison TG, Araujo AB, Kupelian V, O'Donnell AB, McKinlay JB. The relative contributions of aging, health, and lifestyle factors to serum testosterone decline in men. J Clin Endocrinol Metab 2007; 92: 549-55.

Hammond A, Gibson M, Hunt SC, et al. Effect of Roux-en-Y gastric bypass surgery on the steroids and quality of life in obese men. J Clin Endocrinol Metab 2009; 94: 1329-32.

Trasi AM, Abdou R, Kypreos KE. Androgen deficiency and atherosclerosis: The lipid link. Vasc Pharmacol 2009; 51: 303-13.

Jones TH, Saad F. The effects of testosterone on risk factors for, and the mediators of, the atherosclerotic process. Atherosclerosis 2009; 207: 318-27.

Allan CA, Strauss BJ, Burger HG, Forbes EA, McLaughlin RI. Testosterone therapy prevents gain in visceral adipose tissue and loss of skeletal muscle in nonobese aging men. J Clin Endocrinol Metab 2008; 93: 139-46.

Marin P, Holmang S, Gustafsson C, et al. Androgen treatment of abdominally obese men. Obes Res 1993; 1: 245-51.

Snyder PJ, Peachey H, Hannouch P, et al. Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. J Clin Endocrinol Metab 1999; 84: 2647-53.

Kenny AM, Fabregas G, Song C, Biskup B, Bellantonio S. Effects of testosterone on behavior, depression, and cognitive function in older men with mild cognitive loss. J Gerontol A Biol Sci Med Sci 2004; 59: 75-8.

Wittert GA, Chapman JM, Haren MT, Mackintosh S, Coates P, Morley JE. Oral testosterone supplementation increases muscle and decreases fat mass in healthy elderly males with low-normal gonadal status. J Gerontol A Biol Sci Med Sci 2003; 58: 618-25.

Kenny AM, Westwood KM, Gruman CA, Marcello KM, Raisz LG. Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels. J Gerontol A Biol Sci Med Sci 2001; 56: M266-72.

Ferrando AA, Sheffield-Moore M, Yeckel CW, et al. Testosterone administration to older men improves muscle function: molecular and physiological mechanisms. Am J Physiol Endocrinol Metab 2002; 282: E601-7.

Boyanov MA, Boneva Z, Christov VG. Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. Aging Male 2003; 6: 1-7.

Crawford BA, Liu PY, Kean MT, Bleasel JF, Handelsman DJ. Randomized placebo-controlled trial of androgen effects on muscle and bone in men requiring long-term systemic glucocorticoid treatment. J Clin Endocrinol Metab 2003; 88: 3167-76.

Steidle C, Schwartz S, Jacoby K, Sehore T, Smith T, Bachand R. AA2500 testosterone gel normalizes androgen levels in aging men with type 2 diabetes. Eur J Endocrinol 2006; 154: 899-906.

Svartberg J, Agledahl I, Figenchuay Y, Sildnes T, Waterlo K, Jorde R. Testosterone treatment in elderly men with subnormal testosterone levels improves body composition and BMD in the hip. Int J Impot Res 2008; 20: 378-87.

Sheffield-Moore M, Dillan EL, Caspersion SL, et al. A Randomized Pilot Study of Monthly Cycled Testosterone Replacement of Continuous Testosterone Replacement Versus Placebo in Older Men. J Clin Endocrinol Metab 2011; 9(11): 1831-7.

Jones TH, Arver S, Behre HM, et al. Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study). Diabetes Care 2011; 34: 828-37.

Kalinchenko SY, Tishova YA, Mikhailaya GJ, Gooren LJ, Gilgat EI, Saad F. Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: the double-blinded placebo-controlled Moscow study. Clin Endocrinol (Oxf) 2010; 73: 602-12.

Saad F, Haider A, Gilgat EI, Gooren L. J. Age, obesity and inflammation at baseline predict the effects of testosterone administration on the metabolic syndrome. Horm Mol Biol Clin Invest 2011; 6: 193–199.

Witham MD, Avenell A. Interventions to achieve long-term weight loss in obese older people: a systematic review and meta-analysis. Age Aging 2010; 39: 176-84.

Dyson PA, Beatty S, Matthews DR. An assessment of low-carbohydrate or low-fat diets for weight loss at 2 year's follow-up. Diabet Med 2010; 27: 363-4.

Menshikova EV, Ritov VB, Toledo FG, Ferrell RE, Goodpaster BH, Kelley DE. Effects of weight loss and physical activity on skeletal muscle mitochondrial function in obesity. Am J Physiol Endocrinol Metab 2005; 288: E818-25.

Simoneau JA, Veerkamp JH, Turcotte LP, Kelley DE. Markers of capacity to utilize fatty acids in human skeletal muscle: relation to insulin resistance and obesity and effects of weight loss. Faseb J 1999; 13: 2051-60.

Chomontowski P, Dube JJ, Amati F, Moderat exercise attenuates the loss of skeletal muscle mass that occurs with intentional caloric restriction-induced weight loss in older, overweight to obese adults. J Gerontol A Biol Sci Med Sci 2009; 64: 575-80.

Kirwan JP, Barkoukis H, Brooks LM, Marchetti CM, Stetzer BP, Gonzalez F. Exercise training and dietary glycemic load may have synergistic effects on insulin resistance in older obese adults. Ann Nutr Metab 2009; 55: 326-33.

Weinheimer EM, Sands LP, Campbell WW. A systematic review of the separate and combined effects of energy restriction and exercise on fat-free mass in middle-aged and older adults: implications for sarcopenic obesity. Nutr Rev 2010; 68: 375-88.

Solomon TP, Sistrun SN, Krishnan RK, et al. Exercise and diet enhance fat oxidation and reduce insulin resistance in older obese adults. J Appl Physiol 2008; 104: 1313-9.

Sih R, Morley JE, Kaiser FE, Perry HM, 3rd, Patrick P, Ross C. Androgen-replacement therapy depresses the ex vivo production of interleukin-1beta and hypercholesterolaemia in hypogonadal men with type 2 diabetes. J Endocrinol Metab 1997; 82: 2469-75.

Menshikova EV, Ritov VB, Toledo FG, Ferrell RE, Goodpaster BH, Kelley DE. Effects of weight loss and physical activity on skeletal muscle mitochondrial function in obesity. Am J Physiol Endocrinol Metab 2005; 288: E818-25.

Simoneau JA, Veerkamp JH, Turcotte LP, Kelley DE. Markers of capacity to utilize fatty acids in human skeletal muscle: relation to insulin resistance and obesity and effects of weight loss. Faseb J 1999; 13: 2051-60.

Chomontowski P, Dube JJ, Amati F, Moderat exercise attenuates the loss of skeletal muscle mass that occurs with intentional caloric restriction-induced weight loss in older, overweight to obese adults. J Gerontol A Biol Sci Med Sci 2009; 64: 575-80.

Kirwan JP, Barkoukis H, Brooks LM, Marchetti CM, Stetzer BP, Gonzalez F. Exercise training and dietary glycemic load may have synergistic effects on insulin resistance in older obese adults. Ann Nutr Metab 2009; 55: 326-33.
Obesity and Testosterone

[89] Calof OM, Singh AB, Lee ML, et al. Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. J Gerontol A Biol Sci Med Sci 2005; 60: 1451-7.

[90] Rhoden EL, Morgentaler A. Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med 2004; 350: 482-92.

[91] Morgentaler A. Testosterone replacement therapy and prostate cancer. Urol Clin North Am 2007; 34: 555-63.

[92] Morgentaler A, Schulman C. Testosterone and prostate safety. Front Horm Res 2009; 37: 197-203.

[93] Morgentaler A, Lipshultz LI, Bennett R, Sweeney M, Avila D Jr., Khera M. Testosterone therapy in men with untreated prostate cancer. J Urol 2011; 185: 1256-60.

[94] Wang C, Svedlof RS, Iranmanesh A, et al. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. J Clin Endocrinol Metab 2000; 85: 2839-53.

[95] Coviello AD, Kaplan B, Lakshman KM, Chen T, Singh AB, Bhasin S. Effects of graded doses of testosterone on erythropoiesis in healthy young and older men. J Clin Endocrinol Metab 2008; 93: 914-9.

[96] Zitzmann M, Nieschlag E. Androgen receptor gene CAG repeat length and body mass index modulate the safety of long-term intramuscular testosterone undecanoate therapy in hypogonadal men. J Clin Endocrinol Metab 2007; 92: 3844-53.

[97] Ip FF, di Pierro I, Brown R, Cunningham I, Handelsman DJ, Liu PY. Trough serum testosterone predicts the development of polycythemia in hypogonadal men treated for up to 21 years with subcutaneous testosterone pellets. Eur J Endocrinol 2010; 162: 385-90.

[98] Traish AM, Saad F, Feeley RJ, Guay A. The dark side of testosterone deficiency: III. Cardiovascular disease. J Androl 2009; 30: 477-94.

[99] Traish AM, Kypreos KE. Testosterone and cardiovascular disease: an old idea with modern clinical implications. Atherosclerosis 2011; 214: 244-8.

[100] Basaria S, Coviello AD, Travison TG, et al. Adverse events associated with testosterone administration. N Engl J Med 2010; 363: 109-22.

[101] Carson III CC, Rosano G. Exogenous Testosterone, Cardiovascular Events, and Cardiovascular Risk Factors in Elderly Men: A Review of Trial Data. J Sex Med 2012; 9(1): 54-67.

[102] James WP, Caterson ID, Coutinho W, et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med 2010; 363: 905-17.

[103] O'Connor DB, Archer J, Wu FC. Effects of testosterone on mood, aggression, and sexual behavior in young men: a double-blind, placebo-controlled, cross-over study. J Clin Endocrinol Metab 2004; 89: 2837-45.

[104] Zitzmann M, Faber S, Nieschlag E. Association of specific symptoms and metabolic risks with serum testosterone in older men. J Clin Endocrinol Metab 2006; 91: 4335-43.

[105] Marin P, Holmang S, Jonsson L, et al. The effects of testosterone treatment on body composition and metabolism in middle-aged obese men. Int J Obes Relat Metab Disord 1992; 16: 991-7.